Search clinical trials for: TAK-925 Placebo

Total 59123 results

Texas Tech University Health Sciences Center
National Center for Complementary and Integrative Health (NCCIH)

Completed

Green Tea and Tai Chi for Bone Health (GTP-TC-Bone)

Osteoporosis

United States
Takeda

Completed

Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants

Healthy Volunteers

United States
University of California, Irvine
University of California, Davis; University of California, San Francisco

Completed

Maternal Emotions and Diet in Pregnancy (PEDIMet)

Stress, Psychological | Pregnancy Related | Glucose Intolerance During Pregnancy

United States
The University of Hong Kong

Completed

Effectiveness of an Adventure-based Training Programme to Reduce Fatigue for Childhood Cancer Survivors

Childhood Cancer

China
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo; Coordenação de Aperfeiçoamento...

Not yet recruiting

Metabolic and Molecular Responses Under the Effect of Taurine Supplementation With and Without Multicomponent Training

Sarcopenic Obesity
Takeda

Recruiting

A Study About Fazirsiran in People With and Without Liver Problems

Hepatic Impairment

Hungary, Slovakia
Takeda

Terminated

Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Ukraine, Poland, Malaysia, Canada, Peru, Philippines, Hungary, Russian Federation, South Africa, Argentina, Croatia, Thailand
Takeda

Completed

Long-term Study of TAK-875

Diabetes Mellitus

Japan
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

Diabetic Gastroparesis | Idiopathic Gastroparesis

United States, Belgium, Japan, Poland
Chong Kun Dang Pharmaceutical

Unknown

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-825 in Patients With Atrial Fibrillation

Atrial Fibrillation

Korea, Republic of
Alkermes, Inc.

Terminated

A 28 Day Parallel Group Study to Assess the Effects of RDN-929

Healthy

Netherlands
Actelion

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects

Healthy Subjects

United Kingdom
Gilead Sciences

Completed

Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in Human Immunodeficiency Virus (HIV) -1 Infected Adults

HIV-1 Infection

United States
University of Pecs
Harkány Spa Hospital, Harkány, Hungary; National Research, Development and...

Completed

Placebo Development and Validation for Healing Water

Balneology

Hungary
The University of Hong Kong

Completed

Effectiveness of an Integrated Programme in Promoting the Regular Physical Activity Among Childhood Cancer Survivors

Malignant Childhood Neoplasm

China
Bionomics Limited

Completed

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder (PREVAIL)

Social Anxiety Disorder

United States
EMS

Recruiting

Efficacy and Safety of BNP105 in the Treatment of Recurrent Aphthous Stomatitis

Aphthous Stomatitis

Brazil
SK Chemicals Co., Ltd.

Completed

A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PD

Parkinson Disease

Korea, Republic of
Takeda

Terminated

A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism

Hypogonadotropic Hypogonadism

United Kingdom
Takeda

Completed

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection

Gastric Ulcer

Taiwan, China, Korea, Republic of, Philippines
Takeda

Completed

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection

Duodenal Ulcer

Taiwan, China, Korea, Republic of, Philippines
Millennium Pharmaceuticals, Inc.

Completed

A Study to Assess Absolute Bioavailability (ABA) of Mobocertinib (TAK-788) and to Characterize Mass Balance, Pharmacokinetics (PK), Metabolism, and Excretion of Carbon-14 ([14C])-Mobocertinib in Male Healthy Participants

Healthy Volunteers

United States
Takeda

Active, not recruiting

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Spain, Korea, Republic of, Taiwan, Japan, China, Italy, Germany, United Kingdom, Puerto Rico
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
Takeda

Completed

Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants

Influenza Infection
Takeda
Shire; Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Thrombotic Thrombocytopenic Purpura (TTP)

China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
Takeda

Completed

Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation (Oasis Flow)

Hyperlipidemia

Japan
Takeda

Completed

A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Non-Steroid Anti-Inflammatory Drug (NSAID) Therapy

Gastric Ulcer | Duodenal Ulcer

Japan
Rush University Medical Center

Completed

Delays to Influence Snack Choice (DISC)

Food Choice

United States
Takeda

Completed

Double Blind Comparative Study of TAK-875

Diabetic Patients

Japan
Durect

Terminated

DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury

SARS-CoV-2

United States
Takeda

Completed

TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study

Healthy Volunteers

United Kingdom
Zhejiang Hisun Pharmaceutical Co. Ltd.

Completed

Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia (HS-25-III-01)

Primary Hypercholesterolemia
Gilead Sciences

Recruiting

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

United States, Taiwan, Korea, Republic of, India, New Zealand, Belgium, Canada, Italy, Romania, Russian Federation, Hong Kong
University of Pennsylvania
Janssen Scientific Affairs, LLC

Completed

Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U) (VIP-U)

Cardiovascular Disease | Psoriasis

United States
Craig James McClain
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

DUR-928 in Patients With Alcoholic Hepatitis (DUR-928/AH)

Alcoholic Hepatitis

United States
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Thrombotic Thrombocytopenic Purpura (TTP)

United States, Spain, Italy, Greece, United Kingdom, Argentina, Poland, Austria
Takeda

Completed

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

China
Takeda

Completed

Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids

Uterine Fibroids

Japan
Sadat City University

Recruiting

The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Major Depressive Disorder

Egypt
Taiho Pharmaceutical Co., Ltd.

Completed

Study of Trifluridine/Tipiracil (TAS-102) in Patients With Metastatic Colorectal Cancer in Asia (TERRA)

Colorectal Cancer

Korea, Republic of, China, Thailand
Taiho Pharmaceutical Co., Ltd.

Completed

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

Overactive Bladder | Detrusor Underactivity

Japan
Proclara Biosciences, Inc.
Alzheimer's Association

Completed

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

Alzheimer Disease

United States
Seung-Jung Park
CardioVascular Research Foundation, Korea; Boryung Pharmaceutical Co., Ltd

Terminated

Effect of Fimasartan for Modification of Atheroma Vulnerability in DEFERred Coronary Disease (FIMA-DEFER)

Coronary Artery Disease

Korea, Republic of
Takeda
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation

Coagulation Disorder

Belgium, Spain, United States, Canada, Germany, France, Austria, Netherlands
Calithera Biosciences, Inc

Completed

A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Large B-cell, Diffuse

United States, Canada, Germany
Takeda

Completed

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

Postoperative Nausea and Vomiting (PONV)

United States
Millennium Pharmaceuticals, Inc.

Completed

A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants

Healthy Volunteers

United States
Cassava Sciences, Inc.
National Institute on Aging (NIA)

Completed

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients (PTI-125)

Alzheimer Disease

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors

Advanced Solid Tumors, Neoplasms, Advanced Solid

Hungary

Search clinical trials for: TAK-925 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gabon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations